Press Room
Media Coverage
January 26, 2012 - Cohera receives IDE approval to begin TissuGlu U.S. trial
Center Watch News Online “Cohera Medical, a developer of absorbable surgical adhesives and sealants, has received Investigational Device Exemption (IDE) approval from the FDA to begin a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu Surgical Adhesive in the U.S.”
January 25, 2012 - Cohera Medical Receives IDE Approval to Begin Pivotal Clinical Trial for TissuGlu® Surgical Adhesive
TechBurgher “Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (“FDA”) to begin a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu® Surgical Adhesive in the United States.”
January 25, 2012 - Cohera Medical receives approval for surgical adhesive
Pittsburgh Tribune-Review “Cohera Medical Inc., a North Shore medical device company, received approval from the Food and Drug Administration to begin clinical trials for its surgical adhesive.”
January 25, 2012 - FDA approves clinical trial for Cohera’s TissuGlu
Pittsburgh Post-Gazette “Cohera Medical Inc., with offices on the North Side, has received approval from the U.S. Food and Drug Administration to begin a multi-center clinical trial for its surgical adhesive, TissuGlu®.”
January 25, 2012 - FDA Approves Surgical Adhesive for U.S. Study
Outpatient Surgery “The Food and Drug Administration has issued Investigational Device Exemption approval to Cohera Medical’s TissuGlu® surgical adhesive, opening the door for a prospective, multi-center, randomized clinical trial of the product in the U.S.”
January 25, 2012 - Cohera receives FDA IDE approval to initiate U.S. clinical study for TissuGlu
News-Medical “Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration to begin a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu® Surgical Adhesive in the United States.”
January 25, 2012 - FDA grants IDE approval for Cohera TissuGlu Surgical Adhesive
Medical Devices Business Review “The US Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) approval to Cohera Medical’s TissuGlu® Surgical Adhesive.”
January 24, 2012 - Cohera Medical Receives IDE Approval to Begin Pivotal Clinical Trial for TissuGlu Surgical Adhesive
PipelineReview.com “Cohera Medical, Inc.® announced today that it has received IDE approval from the FDA to begin a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu® Surgical Adhesive in the United States.”
January 24, 2012 - Cohera heading into U.S. trials
Pittsburgh Business Times “Surgical adhesive company Cohera Medical Inc. now has the green light to start its U.S. clinical trials for its premiere product TissuGlu®.”
January 24, 2012 - Cohera Medical Gets FDA OK to Start Tissue Glue Tummy Tuck Trial in the US
Plastic Surgery Practice “Cohera Medical, Inc.® has received Investigational Device Exemption (IDE) approval from the FDA to start a prospective, randomized clinical trial for TissuGlu® Surgical Adhesive in the US.”